Overview

Study of Sacituzumab Govitecan-hziy (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-programmed Death Protein 1 (PD-1)/Programmed D

Status:
Not yet recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to compare overall survival (OS) of sacituzumab govitecan-hziy (SG) versus docetaxel in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy and anti-programmed death protein 1 (PD-1)/ programmed death ligand 1 (PD-L1) immunotherapy received either in combination or sequentially. Participants will be randomly assigned in a 1:1 ratio to receive either SG or docetaxel.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Docetaxel